

ABSTRAK

Penelitian ini bertujuan untuk mengetahui dampak pandemi Covid-19 pada kinerja perusahaan sektor kesehatan yang terdaftar di Bursa Efek Indonesia. Objek penelitian ini adalah 17 perusahaan sektor kesehatan yang terdaftar di Bursa Efek Indonesia tahun 2017-2021. Kinerja perusahaan sebagai variabel dependen diproksikan dengan NPM, ROA, ROE, dan *Tobin's Q*. Pengujian dilakukan menggunakan uji non-parametrik dan regresi data panel. Tidak terdapat perbedaan bermakna pada kinerja perusahaan sebelum dan selama pandemi Covid-19 setelah dilakukan pengujian menggunakan *t-Test* dan *Wilcoxon Signed-Rank Test*. Hasil regresi menunjukkan bahwa pandemi Covid-19 tidak memberikan pengaruh terhadap kinerja perusahaan. Hasil penelitian yang menunjukkan bahwa perusahaan sektor kesehatan mampu mempertahankan kinerja selama masa pandemi Covid-19 dapat memberikan implikasi kepada keputusan investor untuk melanjutkan investasi pada sektor ini dan pertimbangan regulator untuk menerapkan kebijakan program Transformasi Kesehatan secara menyeluruh

Kata kunci: kinerja perusahaan, pandemi Covid-19, NPM, ROA, ROE, *Tobin's Q*

ABSTRACT

This study aims to determine the impact of the Covid-19 pandemic on firm performance of health sector companies listed on the Indonesia Stock Exchange. The objects of this research are 17 health sector companies listed on the Indonesia Stock Exchange in 2017-2021. Firm performance as the dependent variable is proxied by NPM, ROA, ROE, and Tobin's Q. Tests were performed using non-parametric tests and panel data regression. There was no significant difference in the company's performance before and during the Covid-19 pandemic after testing using the t-Test and Wilcoxon Signed-Rank Test. The regression results show that the Covid-19 pandemic has not had an effect on company performance. The results of the research showing that health sector companies were able to maintain their performance during the Covid-19 pandemic could have implications for investors' decisions to continue investing in this sector and regulators' considerations for implementing the Health Transformation program policies as a whole.

Keywords: Firm performance, Covid-19 pandemic, NPM, ROA, ROE, Tobin's Q